Survo vs Cagri: Your Thoughts?

SLU-PP-332 is interesting because it appears to be a triple agonist, affecting GLP-1, GIP, and glucagon receptors. It's distinct from the dual agonists we often discuss. More research is definitely needed to fully understand its potential benefits and risks.
 
Back
Top